(UroToday.com) Though the clinical trials leading to approval of life-prolonging therapies in metastatic castrations resistant prostate cancer (mCRPC) included a substantial minority of patients over the age of 75, the efficacy and impact on the quality of life in more senior patients is not clearly established. To gather more information on this question, the authors of this poster performed a retrospective analysis of three clinical trials with control arms of docetaxel therapy (MAINSAIL, ENTHUSE, and VENICE). An age cut-off of 75 was used to delineate groups, and differences in overall survival, as well as the quality of life as assessed by greater than 10 point decrease in FACT-P score, were compared between groups. Covariates for analysis included pain, performance status, and lab values for hemoglobin, albumin, lactate dehydrogenase, and alkaline phosphatase.